• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

选择性雄激素受体调节剂 SARM-2f 激活雄激素受体,增加瘦体重,并降低食蟹猴的血脂水平。

A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys.

机构信息

Oncology Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa, Japan.

出版信息

Pharmacol Res Perspect. 2020 Feb;8(1):e00563. doi: 10.1002/prp2.563.

DOI:10.1002/prp2.563
PMID:32030892
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7005530/
Abstract

SARM-2f a selective androgen receptor (AR) modulator, increases skeletal muscle mass and locomotor activity in rats. This study aimed to clarify its pharmacological effects in monkeys. In reporter assays, the EC values of SARM-2f for rat, monkey, and human AR were 2.5, 3, and 3.6 nmol/L, respectively; those of testosterone were 12, 3.2, and 11 nmol/L, respectively. A single oral administration (10 mg/kg SARM-2f) produced a maximal plasma concentration of 3011 ng/mL, with an area under the 24 hours concentration-time curve of 8152 ng·h/mL in monkeys. Body weight (BW), lean body mass (LBM), and plasma levels of total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, lipoprotein (a), alanine aminotransferase, and asparagine aminotransferase were measured after 4 weeks of treatment with SARM-2f (1, 3, and 10 mg/kg/day, QD, p.o.) or testosterone enanthate (TE; 2 mg/kg/2 weeks, s.c.) in monkeys. BW and LBM were significantly increased by 12% each by SARM-2f at 10 mg/kg, and by 5% and 8%, respectively, by TE, but these effects were not statistically significant. Plasma levels of all lipids were either decreased or showed a tendency to be decreased by SARM-2f. TE decreased the triglyceride level and increased the low-density lipoprotein cholesterol level. Liver marker levels were not changed by either SARM-2f or TE. Our data demonstrated that SARM-2f exerted anabolic effects and produced a lipid profile that differed from that produced by testosterone in monkeys, suggesting that SARM-2f might be useful for diseases such as sarcopenia.

摘要

SARM-2f 是一种选择性雄激素受体 (AR) 调节剂,可增加大鼠的骨骼肌质量和运动活性。本研究旨在阐明其在猴子中的药理学效应。在报告基因检测中,SARM-2f 对大鼠、猴子和人类 AR 的 EC 值分别为 2.5、3 和 3.6 nmol/L,而睾酮的 EC 值分别为 12、3.2 和 11 nmol/L。单次口服(10 mg/kg SARM-2f)可使猴子的血浆最大浓度达到 3011ng/mL,24 小时浓度-时间曲线下面积为 8152ng·h/mL。猴子连续 4 周接受 SARM-2f(1、3 和 10 mg/kg/天,QD,po)或睾酮 enanthate(TE;2 mg/kg/2 周,sc)治疗后,测量体重(BW)、瘦体重(LBM)、总胆固醇、甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、脂蛋白(a)、丙氨酸氨基转移酶和天冬氨酸氨基转移酶的血浆水平。SARM-2f 以 10 mg/kg 使 BW 和 LBM 分别显著增加 12%,TE 使 BW 和 LBM 分别增加 5%和 8%,但这些作用无统计学意义。所有脂质的血浆水平要么降低,要么有降低趋势。SARM-2f 降低了甘油三酯水平,增加了低密度脂蛋白胆固醇水平。SARM-2f 和 TE 均未改变肝标志物水平。我们的数据表明,SARM-2f 在猴子中发挥了合成代谢作用,并产生了不同于睾酮的脂质谱,这表明 SARM-2f 可能对肌少症等疾病有用。

相似文献

1
A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys.选择性雄激素受体调节剂 SARM-2f 激活雄激素受体,增加瘦体重,并降低食蟹猴的血脂水平。
Pharmacol Res Perspect. 2020 Feb;8(1):e00563. doi: 10.1002/prp2.563.
2
Amelioration of sexual behavior and motor activity deficits in a castrated rodent model with a selective androgen receptor modulator SARM-2f.在去势啮齿动物模型中使用选择性雄激素受体调节剂SARM-2f改善性行为和运动活动缺陷。
PLoS One. 2017 Dec 7;12(12):e0189480. doi: 10.1371/journal.pone.0189480. eCollection 2017.
3
Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models.新型选择性雄激素受体调节剂在癌症恶病质模型中对体重减轻和肌肉减少症的预防作用
Oncol Lett. 2017 Dec;14(6):8066-8071. doi: 10.3892/ol.2017.7200. Epub 2017 Oct 17.
4
A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.一种新型选择性雄激素受体调节剂(SARM)MK-4541在前列腺癌异种移植瘤R-3327G中发挥抗雄激素活性,并对去势小鼠的骨骼肌质量和功能具有合成代谢活性。
J Steroid Biochem Mol Biol. 2016 Oct;163:88-97. doi: 10.1016/j.jsbmb.2016.04.007. Epub 2016 Apr 19.
5
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report.LGD-4033与MK-677的使用对身体成分、循环生物标志物以及骨骼肌雄激素和受体含量的影响:一例报告
Exp Physiol. 2022 Dec;107(12):1467-1476. doi: 10.1113/EP090741. Epub 2022 Nov 16.
6
Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical candidate.新型选择性雄激素受体调节剂(SARMs)的合成与生物学评价 第三部分:4-(5-氧代吡咯烷-1-基)苯甲腈衍生物2f作为临床候选药物的发现
Bioorg Med Chem. 2017 Jul 1;25(13):3330-3349. doi: 10.1016/j.bmc.2017.04.018. Epub 2017 Apr 13.
7
Pharmacological characterization of an imidazolopyrazole as novel selective androgen receptor modulator.一种咪唑并吡唑作为新型选择性雄激素受体调节剂的药理学特征。
J Steroid Biochem Mol Biol. 2013 Mar;134:51-8. doi: 10.1016/j.jsbmb.2012.10.015. Epub 2012 Oct 23.
8
Proteome-wide muscle protein fractional synthesis rates predict muscle mass gain in response to a selective androgen receptor modulator in rats.全蛋白质组范围的肌肉蛋白质分数合成率可预测大鼠对选择性雄激素受体调节剂的反应中肌肉质量的增加。
Am J Physiol Endocrinol Metab. 2016 Mar 15;310(6):E405-17. doi: 10.1152/ajpendo.00257.2015. Epub 2015 Dec 29.
9
Identification and Synthesis of Selected In Vitro Generated Metabolites of the Novel Selective Androgen Receptor Modulator (SARM) 2f.新型选择性雄激素受体调节剂(SARM)2f 的鉴定和合成及其在体外生成的代谢物。
Molecules. 2023 Jul 20;28(14):5541. doi: 10.3390/molecules28145541.
10
The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.LGD-4033,一种新型非甾体口服、选择性雄激素受体调节剂,在健康年轻男性中的安全性、药代动力学和作用。
J Gerontol A Biol Sci Med Sci. 2013 Jan;68(1):87-95. doi: 10.1093/gerona/gls078. Epub 2012 Mar 28.

引用本文的文献

1
A SARM a Day Keeps the Weakness Away: A Computational Approach for Selective Androgen Receptor Modulators (SARMs) and Their Interactions with Androgen Receptor and 5‑Alpha Reductase Proteins.每天一片选择性雄激素受体调节剂,远离虚弱:一种针对选择性雄激素受体调节剂(SARMs)及其与雄激素受体和5-α还原酶蛋白相互作用的计算方法。
ACS Omega. 2025 Jul 18;10(29):31649-31667. doi: 10.1021/acsomega.5c02504. eCollection 2025 Jul 29.
2
The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP-1 Agonists: A Literature Review.选择性雄激素受体调节剂(SARMs)和抗肌生成抑制素药物在解决GLP-1激动剂引起的瘦体重损失方面的潜力:一项文献综述
J Diabetes. 2025 Aug;17(8):e70119. doi: 10.1111/1753-0407.70119.
3

本文引用的文献

1
Guideline of guidelines: testosterone therapy for testosterone deficiency.指南的指南:睾酮治疗睾酮缺乏症。
BJU Int. 2019 Nov;124(5):722-729. doi: 10.1111/bju.14899. Epub 2019 Sep 11.
2
Statins increase Lp(a) plasma level: is this clinically relevant?他汀类药物会升高血浆脂蛋白(a)水平:这在临床上有相关性吗?
Eur Heart J. 2020 Jun 21;41(24):2285-2287. doi: 10.1093/eurheartj/ehz505.
3
Sarcopenia.肌肉减少症。
Androgens as the "old age stick" in skeletal muscle.
雄激素作为骨骼肌中的“衰老棒”。
Cell Commun Signal. 2025 Apr 3;23(1):167. doi: 10.1186/s12964-025-02163-6.
4
Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases.选择性雄激素受体调节剂的使用及相关不良事件,包括药物性肝损伤:疑似病例分析。
Eur J Clin Pharmacol. 2024 Feb;80(2):185-202. doi: 10.1007/s00228-023-03592-3. Epub 2023 Dec 7.
5
Identification and Synthesis of Selected In Vitro Generated Metabolites of the Novel Selective Androgen Receptor Modulator (SARM) 2f.新型选择性雄激素受体调节剂(SARM)2f 的鉴定和合成及其在体外生成的代谢物。
Molecules. 2023 Jul 20;28(14):5541. doi: 10.3390/molecules28145541.
6
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.选择性雄激素受体调节剂激活经典的前列腺癌雄激素受体程序并抑制癌症生长。
J Clin Invest. 2021 May 17;131(10). doi: 10.1172/JCI146777.
Lancet. 2019 Jun 29;393(10191):2636-2646. doi: 10.1016/S0140-6736(19)31138-9. Epub 2019 Jun 3.
4
Statin therapy increases lipoprotein(a) levels.他汀类药物治疗会升高脂蛋白(a)水平。
Eur Heart J. 2020 Jun 21;41(24):2275-2284. doi: 10.1093/eurheartj/ehz310.
5
Cardiovascular and Cerebrovascular Safety of Testosterone Replacement Therapy Among Aging Men with Low Testosterone Levels: A Cohort Study.男性低睾酮水平与衰老相关心血管和脑血管安全性:一项队列研究。
Am J Med. 2019 Sep;132(9):1069-1077.e4. doi: 10.1016/j.amjmed.2019.03.022. Epub 2019 Apr 3.
6
International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management.国际肌少症临床实践指南(ICFSR):筛查、诊断和管理。
J Nutr Health Aging. 2018;22(10):1148-1161. doi: 10.1007/s12603-018-1139-9.
7
Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia-Review and Expert Opinion.新型非肽类 ghrelin 类似物氨来占诺治疗晚期非小细胞肺癌(NSCLC)合并恶液质患者的疗效:综述与专家观点。
Int J Mol Sci. 2018 Nov 5;19(11):3471. doi: 10.3390/ijms19113471.
8
Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal.脂蛋白(a)与动脉粥样血栓事件的二级预防:批判性评价。
J Clin Lipidol. 2018 Nov-Dec;12(6):1358-1366. doi: 10.1016/j.jacl.2018.08.012. Epub 2018 Sep 11.
9
Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models.新型选择性雄激素受体调节剂在癌症恶病质模型中对体重减轻和肌肉减少症的预防作用
Oncol Lett. 2017 Dec;14(6):8066-8071. doi: 10.3892/ol.2017.7200. Epub 2017 Oct 17.
10
Amelioration of sexual behavior and motor activity deficits in a castrated rodent model with a selective androgen receptor modulator SARM-2f.在去势啮齿动物模型中使用选择性雄激素受体调节剂SARM-2f改善性行为和运动活动缺陷。
PLoS One. 2017 Dec 7;12(12):e0189480. doi: 10.1371/journal.pone.0189480. eCollection 2017.